Madrigal Pharmaceuticals (NASDAQ: MDGL) reported an insider sale by its general counsel that reduced her holdings by 360 common shares. According to a Form 4 filing with the Securities and Exchange Commission, Kelley Shannon T sold the shares on March 6, 2026, at a per-share price of $431.94, generating proceeds of $155,498.
The filing notes the sale took place while the stock was trading at $433.36. Analysis from InvestingPro cited alongside the transaction characterizes the company as undervalued relative to its Fair Value.
The Form 4 also discloses additional March transactions involving Kelley Shannon T. On March 4, 2026, she acquired 4,017 shares of common stock with a declared value of $0. That same day, she was granted 5,022 stock options. Those options are exercisable to purchase common shares at a strike price of $434.80 and carry an expiration date of 2036-03-04.
Financial details included in investor materials underline the company’s operating profile: Madrigal reported gross profit margins of 94%. Despite that margin strength, the company remained unprofitable over the last twelve months, according to the information provided.
Separately, Madrigal released fourth-quarter 2025 results that showed a mixed performance versus expectations. The company posted earnings per share of -$2.57, missing the forecasted -$0.60. Revenue for the quarter, however, came in at $321.1 million, topping the $310.82 million estimate.
The company attributed continued revenue momentum in part to Rezdiffra, its leading commercial product. The filing and public disclosures state that Rezdiffra has generated nearly $1 billion in net sales since its commercial debut.
On the analyst front, two firms reiterated Buy ratings on Madrigal. H.C. Wainwright maintained a price target of $620.00, while Truist Securities kept a $640.00 target. Truist emphasized that the company’s effective therapy is gaining traction in an expanding market, a factor cited in its reiteration. These analyst positions were presented as part of ongoing coverage reflecting Madrigal’s strategic efforts to sustain its market standing.
For investors seeking deeper financial modeling and valuation work, a Pro Research Report on MDGL is available through InvestingPro. The platform lists that report as one of more than 1,400 research reports it offers.
This article presents the transactions and company disclosures as reported in SEC filings and company reporting, without extrapolation beyond those statements.